Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Gardasil-9 and Cervarix in 9-10 Year Olds
NCT02567955Phase 3Completed
- Sponsor
- Université Laval
- Start
- Sep 2015
- Primary completion
- Sep 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine, human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection, sponsored by Université Laval. Started Sep 2015; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccinehuman papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT02567955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567955.